Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G6 | O60733 | 2/20 | 0.62 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.62 |
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823187 | 1.00 | PLA2G6 (0.62) | PLA2G6PLA2G4AFASNNAAAABCB1 | |
| SCHEMBL10368775 | 0.98 | PLA2G6 (0.61) | PLA2G6PLA2G4AFASNNAAAABCB1 | |
| SCHEMBL10369079 | 0.98 | PLA2G6 (0.61) | PLA2G6PLA2G4AFASNNAAAABCB1 | |
| SCHEMBL10368566 | 0.98 | PLA2G6 (0.61) | PLA2G6PLA2G4AFASNNAAAABCB1 | |
| SCHEMBL19540551 | 0.88 | FASN (0.63) | PLA2G6PLA2G4AFASNNAAAABCB1 | |
| SCHEMBL6869282 | 0.88 | FASN (0.63) | PLA2G6PLA2G4AFASNNAAAABCB1 | |
| SCHEMBL6823386 | 0.80 | PLA2G6 (0.58) | PLA2G6PLA2G4AFASNNAAA | |
| SCHEMBL19514935 | 0.78 | PLA2G6 (0.84) | PLA2G6PLA2G4AFASNNAAA | |
| SCHEMBL19514903 | 0.78 | PLA2G6 (0.84) | PLA2G6PLA2G4AFASNNAAA | |
| SCHEMBL19514898 | 0.78 | PLA2G6 (0.84) | PLA2G6PLA2G4AFASNNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871439-B1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |